MetaRNA · Project

RNA Sensors That Read Individual Cell Metabolism for Diagnostics and Biotech

healthPrototypeTRL 3Thin data (2/5)

Imagine trying to understand a crowd by only measuring the average mood — you'd miss the one person about to faint. That's how most metabolism tests work today: they measure entire cell populations at once, hiding what individual cells are doing differently. MetaRNA trained 15 researchers to build tiny RNA-based sensors that can peek inside single cells and read their metabolic activity one by one. These tools could eventually spot disease-related metabolic quirks that bulk measurements completely miss.

By the numbers

early-stage researchers trained at the intersection of RNA and metabolism

consortium partners across 6 countries

industry partners in the training network

SMEs involved in the project

deliverables produced

research groups from metabolic and RNA fields

The business problem

What needed solving

Most methods for analyzing cell metabolism look at entire cell populations at once, averaging out critical differences between individual cells. This is a major blind spot: evidence shows that cell-to-cell metabolic differences matter for disease progression, drug response, and bioprocess efficiency — but until now, there were almost no tools to measure metabolism at the single-cell level.

The solution

What was built

The project delivered 22 outputs including an in vivo screening system for optimizing metabolite-sensing aptamers — RNA molecules engineered to detect specific metabolites inside living cells. The network also produced 15 trained specialists with combined expertise in RNA technology and metabolism research.

Audience

Who needs this

In vitro diagnostics companies developing single-cell assaysPharma companies running cell-based drug screeningIndustrial biotech firms optimizing production strainsResearch tool companies selling cell analysis instrumentsClinical labs interested in precision metabolic profiling

Business applications

Who can put this to work

In Vitro Diagnostics

mid-size

Target: Companies developing single-cell diagnostic assays or liquid biopsy platforms

If you are a diagnostics company struggling to detect disease at early stages because your assays average out signals across millions of cells — this project developed RNA-based metabolite sensors and a screening system for optimizing them. These aptamer-based tools can distinguish metabolic differences at the single-cell level, potentially enabling earlier and more precise disease detection.

Biopharmaceuticals

enterprise

Target: Drug development firms using cell-based screening or metabolic profiling

If you are a pharma R&D team running drug screens but getting inconsistent results because cell populations behave differently cell-to-cell — MetaRNA created RNA sensors that measure metabolism in individual cells. This could help you identify which cell subpopulations respond to drug candidates, improving hit rates in screening campaigns.

Industrial Biotechnology

SME

Target: Biotech companies optimizing microbial production strains

If you are a biotech company engineering microbes for chemical production but facing yield inconsistency because only some cells in your culture actually produce well — MetaRNA developed metabolite-sensing aptamers with an in vivo screening system. This could let you sort and select the best-performing individual cells from a mixed population, improving strain development.

Frequently asked

Quick answers

What would it cost to license or access these RNA sensor technologies?

Based on available project data, MetaRNA was a Marie Curie training network (MSCA-ITN-ETN), meaning its primary output was trained researchers rather than a single licensable product. Costs would depend on negotiating with Rijksuniversiteit Groningen or the specific partner that developed the aptamer screening system. Expect academic licensing terms.

Can these RNA sensors work at industrial scale?

The project developed an in vivo screening system for optimizing metabolite-sensing aptamers, but this was demonstrated within a research context. Scaling to industrial throughput — such as high-throughput cell sorting in bioreactors — would require significant further engineering and validation beyond what MetaRNA delivered.

Who owns the intellectual property from this project?

IP from MSCA-ITN projects typically stays with the institution where the work was performed. With 15 partners across 6 countries including 5 industry partners and 4 SMEs, IP ownership may be distributed. Contact Rijksuniversiteit Groningen as coordinator for clarification on specific technologies.

Is this technology ready for regulatory approval in diagnostics?

Based on available project data, the RNA sensors are still at an early research stage. The project focused on developing and optimizing the sensor tools themselves, not on clinical validation. Any diagnostic application would need extensive regulatory work before reaching patients.

How long before this could be integrated into existing lab workflows?

MetaRNA ended in June 2019. The screening system for metabolite-sensing aptamers was demonstrated as a deliverable, but integration into commercial workflows would require additional development. Companies interested should look for follow-up projects or spin-offs from the 15 trained researchers who graduated from this network.

Which industry partners were involved and what did they contribute?

The consortium included 5 industry partners and 4 SMEs out of 15 total partners across 6 countries. The 6 private sector partners joined 8 academic research groups to provide industrial training and real-world application context for the 15 early-stage researchers.

Consortium

Who built it

MetaRNA brought together 15 partners from 6 countries (CH, DE, DK, FR, NL, UK), with a healthy 33% industry ratio — 5 industry partners including 4 SMEs alongside 6 universities and 4 research organizations. This strong industry presence for a training network signals genuine commercial interest in RNA-based metabolite sensing. The coordinator, Rijksuniversiteit Groningen in the Netherlands, is a well-established research university. The mix of 8 academic research groups and 6 private sector partners created a pipeline where 15 trained researchers gained both scientific depth and industry exposure, making them potential hires or collaborators for companies entering this space.

RIJKSUNIVERSITEIT GRONINGENCoordinator · NL
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEparticipant · FR
DSM FOOD SPECIALTIES BVparticipant · NL
BIOSYNTIA APSparticipant · DK
KOBENHAVNS UNIVERSITETparticipant · DK
RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONNparticipant · DE
APTAIT GMBHpartner · DE
UNITED KINGDOM RESEARCH AND INNOVATIONparticipant · UK
EVOLVA AGpartner · CH
DANMARKS TEKNISKE UNIVERSITETparticipant · DK
TECHNISCHE UNIVERSITAT DARMSTADTparticipant · DE
UNIVERSITY OF WARWICKparticipant · UK
THE FRANCIS CRICK INSTITUTE LIMITEDparticipant · UK
CENTRE TECHNOLOGIQUE NOUVELLE-AQUITAINE COMPOSITES & MATERIAUX AVANCESpartner · FR

How to reach the team

Rijksuniversiteit Groningen (Netherlands) — the coordinator of this 15-partner network. Google the project name + coordinator to find the lead PI.

Order a report on this consortium See RIJKSUNIVERSITEIT GRONINGEN profile →

Next steps

Talk to the team behind this work.

Want to connect with the MetaRNA team or explore RNA-based sensor technologies for your diagnostics or biotech workflow? SciTransfer can arrange an introduction and provide a detailed technology brief.

Order a report on this topic More in Health & Biomedical